- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease
American Journal of Bioethics Neuroscience 14 (3):332-335 (2023)
Abstract
It is a tale of two Pfizers. In 2018 they abandoned research into the leading cause of dementia, Alzheimer’s Disease (AD) (Hawkes 2018). In 2021, they developed the first vaccine for Covid-19 to re...Other Versions
No versions found
My notes
Similar books and articles
Personal Utility and Early Intervention in Alzheimer’s Disease.Ana M. Tyler, Jennifer S. Yokoyama & Jalayne J. Arias - 2021 - American Journal of Bioethics Neuroscience 12 (4):226-228.
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.Matthew Herder - 2023 - Journal of Law, Medicine and Ethics 51 (4):900-919.
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease.Timothy Daly, Karl Herrup & Alberto J. Espay - 2024 - American Journal of Bioethics Neuroscience 15 (2):80-81.
A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. [REVIEW]Bor Luen Tang & Nicole Shu Ling Yeo-Teh - 2023 - Science and Engineering Ethics 29 (1):1-18.
Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer’s Disease and Related Disorders.Adrian Carter, Myfanwy Graham, Wayne Hall, Michaela Barber & John Gardner - 2023 - American Journal of Bioethics Neuroscience 14 (2):129-131.
Of Meatballs And Invasive Neurotechnological Trials: Additional Considerations for Complex Clinical Decisions.John Noel M. Viaña, Adrian Carter & Frederic Gilbert - 2018 - American Journal of Bioethics Neuroscience 9 (2):100-104.
Alzheimer's in 3D culture: Challenges and perspectives.Carla D'Avanzo, Jenna Aronson, Young Hye Kim, Se Hoon Choi, Rudolph E. Tanzi & Doo Yeon Kim - 2015 - Bioessays 37 (10):1139-1148.
Publishing the Biotechnical Futures of Alzheimer’s Disease.James Rupert Fletcher - 2023 - American Journal of Bioethics Neuroscience 14 (2):124-126.
More than a medical condition: Qualitative analysis of media representations of dementia and Alzheimer’s disease.Jana Plichtová & Anna Šestáková - 2020 - Human Affairs 30 (3):382-398.
Psychedelic Research for Dementia Risks Perpetuating Structural Failures and Inadequacies in Aged Care.Hojjat Soofi & Cynthia Forlini - 2023 - American Journal of Bioethics Neuroscience 14 (2):131-134.
Analytics
Added to PP
2022-04-08
Downloads
29 (#632,484)
6 months
16 (#283,351)
2022-04-08
Downloads
29 (#632,484)
6 months
16 (#283,351)
Historical graph of downloads
Citations of this work
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease.Timothy Daly, Karl Herrup & Alberto J. Espay - 2024 - American Journal of Bioethics Neuroscience 15 (2):80-81.
References found in this work
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?Holly Fernandez Lynch, Arthur Caplan, Patricia Furlong & Alison Bateman-House - 2021 - American Journal of Bioethics 21 (12):4-19.
On the reconceptualization of Alzheimer’s disease.Maartje Schermer & Edo Richard - 2018 - Bioethics 33 (1):138-145.
Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2021 - Journal of Medical Ethics 47 (9):608-614.
The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols.Timothy Daly, Ignacio Mastroleo, David Gorski & Stéphane Epelbaum - 2020 - Theoretical Medicine and Bioethics 41 (5):223-237.
Alzheimer's and Aducanumab: Unjust Profits and False Hopes.Leonard M. Fleck - 2021 - Hastings Center Report 51 (4):9-11.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-9b866bbb8-sl6b2 uwo